Medarex is causing a stir on StockTwits due to a new prostate cancer treatment called Ipilimumab. MEDX has had a solid run since forming a double top breakout buy signal on April 22nd, but it has stopped at a level that served as support in June 2006. With the overall market continuing to show weakness,…